
Mythic Therapeutics leverages FateControl tech for innovative ADCs, targeting cancer, sparing normal cells.
Founded with a mission to revolutionize cancer treatment, Mythic Therapeutics focuses on developing advanced Antibody Drug Conjugates (ADCs) using their proprietary FateControlâ„¢ technology. This innovative platform enhances the precision of ADCs, ensuring that chemotherapy is delivered directly to cancerous cells while sparing healthy tissues. By increasing the efficacy and reducing the toxicity of cancer treatments, Mythic Therapeutics aims to provide more effective and safer therapeutic options for a wide range of cancer types.
Notable figures associated with Mythic Therapeutics include experts in oncology and biotechnology, supported by a robust network of investors committed to advancing cancer treatment. The company has achieved significant milestones, including the successful development and application of FateControlâ„¢ technology, which has shown promising results in preclinical studies. Mythic Therapeutics' impact lies in its potential to transform the landscape of cancer therapy, offering hope for more targeted and less harmful treatment options.

Adcentrx Therapeutics
adcentrx.com

PanTher Therapeutics
panthertx.com

Mersana Therapeutics
mersana.com

Fortis Therapeutics

Mediar Therapeutics
mediartx.com

MBrace Therapeutics
mbracetrx.com

Window Therapeutics
windowtx.com

Advanced Chemotherapy Technologies

Theradaptive
theradaptive.com

Faeth Therapeutics

Anthos Therapeutics

Metheor Therapeutics

Tactiva Therapeutics

Starton Therapeutics

Telo Therapeutics
Companies similar to Mythic Therapeutics include Adcentrx Therapeutics, PanTher Therapeutics, Mersana Therapeutics and Fortis Therapeutics.
Mythic Therapeutics was founded in 2017.
Mythic Therapeutics' headquarters is located in Waltham, MA, US.
Mythic Therapeutics' most recent funding round was for $103M (USD) in December 2021.
As of Dec 15, 2021, Mythic Therapeutics has raised a total of $126.6M (USD).
Mythic Therapeutics has 46 employees as of Feb 5, 2024.